Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Payables: 2019-2025

Historic Payables for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $18.4 million.

  • IDEAYA Biosciences' Payables rose 46.68% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year increase of 66.31%. This contributed to the annual value of $15.4 million for FY2024, which is 133.72% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Payables stood at $18.4 million for Q3 2025, which was up 6.73% from $17.3 million recorded in Q2 2025.
  • IDEAYA Biosciences' 5-year Payables high stood at $18.4 million for Q3 2025, and its period low was $1.3 million during Q1 2021.
  • In the last 3 years, IDEAYA Biosciences' Payables had a median value of $12.6 million in 2024 and averaged $11.4 million.
  • Data for IDEAYA Biosciences' Payables shows a peak YoY soared of 180.30% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Payables stood at $2.1 million in 2021, then skyrocketed by 103.81% to $4.3 million in 2022, then skyrocketed by 54.16% to $6.6 million in 2023, then skyrocketed by 133.72% to $15.4 million in 2024, then soared by 46.68% to $18.4 million in 2025.
  • Its Payables was $18.4 million in Q3 2025, compared to $17.3 million in Q2 2025 and $17.6 million in Q1 2025.